Xilio Therapeutics, Inc. (NASDAQ:XLO - Get Free Report) major shareholder Gilead Sciences, Inc. purchased 485,250 shares of the firm's stock in a transaction on Tuesday, April 2nd. The stock was acquired at an average cost of $0.76 per share, with a total value of $368,790.00. Following the transaction, the insider now directly owns 7,345,473 shares in the company, valued at $5,582,559.48. The purchase was disclosed in a filing with the SEC, which is available at this link. Large shareholders that own more than 10% of a company's stock are required to disclose their transactions with the SEC.
Xilio Therapeutics Price Performance
Shares of XLO stock opened at $1.30 on Thursday. Xilio Therapeutics, Inc. has a 52 week low of $0.49 and a 52 week high of $3.67. The firm has a 50 day moving average of $0.73 and a two-hundred day moving average of $1.13.
Hedge Funds Weigh In On Xilio Therapeutics
Several hedge funds and other institutional investors have recently added to or reduced their stakes in XLO. Citadel Advisors LLC purchased a new position in Xilio Therapeutics in the 4th quarter valued at approximately $28,000. Charles Schwab Investment Management Inc. purchased a new position in Xilio Therapeutics in the 2nd quarter valued at approximately $31,000. Dimensional Fund Advisors LP purchased a new position in Xilio Therapeutics in the 1st quarter valued at approximately $57,000. Morgan Stanley raised its holdings in shares of Xilio Therapeutics by 274.4% in the 4th quarter. Morgan Stanley now owns 25,611 shares of the company's stock valued at $69,000 after purchasing an additional 18,771 shares in the last quarter. Finally, Bridgeway Capital Management LLC raised its holdings in shares of Xilio Therapeutics by 40.7% in the 4th quarter. Bridgeway Capital Management LLC now owns 155,481 shares of the company's stock valued at $86,000 after purchasing an additional 45,000 shares in the last quarter. Hedge funds and other institutional investors own 54.29% of the company's stock.
Xilio Therapeutics Company Profile
(
Get Free Report)
Healthcare Takes A Big Step Forward With The Help Of AI
From The Bull Report | Ad
The average doctor can diagnose an illness correctly 50-90% of the time.
But one innovative company's medical AI gets it right 92%+.
Click here to see why this small company is trusted by the Mayo Clinic
Xilio Therapeutics, Inc, a clinical-stage biotechnology company, discovers and develops tumor-activated immuno-oncology therapies. Its checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 1 clinical trial for patients with advanced solid tumors.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
